{"publication_id":"12edec41-aa8d-4c5c-9df1-807b8847f8a1","screening":{"identified":48,"screened":48,"excluded":0,"included":48,"included_or_retained":48,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"48 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]},"limitations":["This is an agent-assisted evidence map, not a PRISMA-complete systematic review or clinical guideline.","It is not PROSPERO-registered and should not be read as medical advice.","Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."],"contradictions":["Positive study-level signals are not the dominant direction in any outcome class; null signals are summarized in the contextual adjacent evidence, cardiometabolic, and muscle function outcome classes; negative signals are not the dominant direction in any outcome class; mixed or heterogeneous signals are summarized in the mechanism, mortality and survival, frailty, and immune and inflammation outcome classes. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.","The conclusion is that Growth differentiation factor 11 should be treated as a bounded geroscience hypothesis: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.","31 included sources were assigned to this outcome class. Directional coding: mixed=1, negative=4, null=22, positive=2, unclear=2. Directness coding: indirect=31.","2 included sources were assigned to this outcome class. Directional coding: mixed=1, null=1. Directness coding: indirect=2.","Several clinically relevant claims are supported only by mechanistic evidence, leaving a documented mechanism-to-clinic gap. Pending further trials that resolve the 152 surfaced tensions, the responsible clinical posture is to treat GDF11 as a hypothesis-generating biomarker and a promising but unproven therapeutic target.","Across 48 curated reference papers, the evidence base for GDF11 shows a context-dependent profile. Positive signals appear in: contextual other. Negative signals appear in: contextual other, mechanism. Null findings dominate: contextual other, cardiometabolic. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The GDF11 anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established.","| contextual adjacent evidence | 0 | 31 | mixed, negative, null, positive, unclear | conflict-resolution gap |","| mortality and survival | 0 | 2 | mixed, null | direct interventional hard-endpoint gap |"]}